Ninety-Seven Percent of Insurance Denials in Pediatric Proton Patients Overturned on Appeal
August 17, 2017
FDA OKs new drug to treat all forms of hepatitis C
August 18, 2017
Show all

Skewing the Aim of Targeted Cancer Therapies

Targeted gene-based cancer therapies have not been uniformly successful.

Headlines, of late, have touted the successes of targeted gene-based cancer therapies, such as immunotherapies, but, unfortunately, also their failures.

Broad inadequacies in a widespread biological concept that affects cancer research could be significantly deflecting the aim of such targeted drugs, according to a new study. A team exploring genetic mechanisms in cancer at the Georgia Institute of Technology has found evidence that a prevailing concept about how cells produce protein molecules, particularly when applied to cancer, could be erroneous as much as two-thirds of the time.

Prior studies by other researchers have also critiqued this concept about the pathway leading from genetic code to proteins, but this new study, led by cancer researcher John McDonald, has employed rare analytical technology to explore it in unparalleled detail. The study also turned up novel evidence for regulating mechanisms that could account for the prevailing concept’s apparent shortcomings.

Read full article: Skewing the Aim of Targeted Cancer Therapies

Read Full Article: Skewing the Aim of Targeted Cancer Therapies 

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.